SEC Form 4 · accession 0001796439-26-000003
Royalty Pharma plc · RPRX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Catherine M. Engelbert
Director
Period of report
Jun 5, 2026
Accepted (ET)
Jun 8, 2026 · 4:22 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001802768
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Class A Ordinary SharesF1 | Jun 5, 2026 | A | 4,545 | $0.00 | A | 55,673 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Reflects an award of restricted stock units under the Issuer's 2020 Independent Director Equity Incentive Plan (the "Plan") that is generally scheduled to vest 100% on the earlier of (i) the one-year anniversary of the grant date and (ii) the date of the annual meeting of the Issuer's shareholders in the first calendar year following the grant date, subject to the terms of the Plan and the applicable award agreement thereunder.